Merck & Company, Inc. (NYSE:MRK)‘s stock had its “hold” rating reissued by Cowen and Company in a research report issued on Friday. They currently have a $70.00 target price on the stock. Cowen and Company’s price objective would indicate a potential upside of 9.61% from the stock’s current price.

Several other brokerages also recently commented on MRK. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $74.00 target price (up from $70.00) on shares of Merck & in a report on Thursday, July 27th. Citigroup Inc. set a $65.00 target price on shares of Merck & and gave the stock a “hold” rating in a report on Wednesday, July 5th. Zacks Investment Research upgraded shares of Merck & from a “hold” rating to a “buy” rating and set a $73.00 target price on the stock in a report on Friday, May 26th. BidaskClub downgraded shares of Merck & from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Finally, Piper Jaffray Companies set a $70.00 price objective on shares of Merck & and gave the company a “buy” rating in a report on Saturday, July 29th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $69.74.

Merck & (NYSE:MRK) opened at 63.86 on Friday. Merck & has a 12 month low of $58.29 and a 12 month high of $66.80. The company’s 50-day moving average is $62.79 and its 200-day moving average is $63.77. The stock has a market capitalization of $174.17 billion, a P/E ratio of 34.57 and a beta of 0.80.

Merck & (NYSE:MRK) last announced its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the company posted $0.93 EPS. Equities analysts anticipate that Merck & will post $3.88 earnings per share for the current year.

WARNING: “Merck &’s (MRK) Hold Rating Reiterated at Cowen and Company” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/01/merck-s-mrk-hold-rating-reiterated-at-cowen-and-company.html.

A number of institutional investors have recently added to or reduced their stakes in MRK. Forte Capital LLC ADV boosted its position in Merck & by 5.6% in the first quarter. Forte Capital LLC ADV now owns 21,424 shares of the company’s stock worth $1,361,000 after buying an additional 1,130 shares during the period. First National Bank of Mount Dora Trust Investment Services boosted its position in Merck & by 23.9% in the first quarter. First National Bank of Mount Dora Trust Investment Services now owns 66,505 shares of the company’s stock worth $4,226,000 after buying an additional 12,840 shares during the period. Stock Yards Bank & Trust Co. boosted its position in Merck & by 7.5% in the first quarter. Stock Yards Bank & Trust Co. now owns 53,798 shares of the company’s stock worth $3,418,000 after buying an additional 3,765 shares during the period. Berson & Corrado Investment Advisors LLC boosted its position in Merck & by 11.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 8,086 shares of the company’s stock worth $514,000 after buying an additional 850 shares during the period. Finally, S&CO Inc. boosted its position in Merck & by 1.1% in the first quarter. S&CO Inc. now owns 388,723 shares of the company’s stock worth $24,699,000 after buying an additional 4,054 shares during the period. 73.00% of the stock is owned by hedge funds and other institutional investors.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.